• 1
    Schindler AE. Progestogen deficiency and endometrial cancer risk. Maturitas 2009;62:3347.
  • 2
    Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012;62:1029.
  • 3
    Hedley AA, Ogden CL, Johnson CL, Carroll MD, Curtin LR, Flegal KM. Prevalence of overweight and obesity among US children, adolescents, and adults, 1999-2002. JAMA 2004;291:284750.
  • 4
    Centers for Disease Control and Prevention. Obesity trends among US adults between 1985 and 2008.
  • 5
    Linkov F, Edwards E, Balk J, Yurkovetsky Z, Stadterman B, Lokshin A, et al. Endometrial hyperplasia, endometrial cancer and prevention: Gaps in existing research of modifiable risk factors. Eur J Cancer 2008; 44: 163244.
  • 6
    Walker JL, Zuna RE. Endometrial Hyperplasia, Estrogen therapy, and the prevention of endometrial cancer. In: Disaia PJ and Creasman WT, editors. Clinical Gynecologic Oncology, 7th edn. Mosby Elsevier: Philadelphia, PA; 2007; pp. 125–46.
  • 7
    Mutter GL. Diagnosis of premalignant endometrial disease. J Clin Pathol 2002;55:32631.
  • 8
    Kurman RJ, Kaminski PF, Norris HJ. The behavior of endometrial hyperplasia. A long-term study of “untreated” hyperplasia in 170 patients. Cancer 1985;56:40312.
  • 9
    Schirmer B. Morbid Obesity. In: Townsend CM, Beauchamp RD, Evers BM, Mattox KL, editors. Sabiston Textbook of Surgery, 17th edn. Philadelphia, PA: Elsevier; 2004. pp. 35799.
  • 10
    Teitelman M, Grotegut CA, Williams NN, Lewis JD. The impact of bariatric surgery on menstrual patterns. Obes Surg 2006;16:145763.
  • 11
    Perugini RA, Malkani S. Remission of type 2 diabetes mellitus following bariatric surgery: review of mechanisms and presentation of the concept of ‘reversibility’. Curr Opin Endocrinol Diabetes Obes 2011;18:11928.
  • 12
    Woelnerhanssen B, Peterli R, Steinert RE, Peters T, Borbély Y, Beglinger C. Effects of postbariatric surgery weight loss on adipokines and metabolic parameters: comparison of laparoscopic Roux-en-Y gastric bypass and laparoscopic sleeve gastrectomy-a prospective randomized trial. Surg Obes Relat Dis 2011;7:5618.
  • 13
    Gosman GG, Katcher HI, Legro RS. Obesity and he role of gut and adipose hormones in female reproduction. Hum Reprod Update 2006;12:585601.
  • 14
    Viola AS, Gouveia D, Andrade L, Aldrighi JM, Viola CFM, Bahamondes L. Prevalence of endometrial cancer and hyperplasia in non-symptomatic overweight and obese women. Aust N Z J Obstet Gynaecol 2008;48:20713.
  • 15
    Smith RA, Cokkinides V, Brawley OW. Cancer screening in the United States, 2009: a review of current American Cancer Society guidelines and issues in cancer screening. CA Cancer J Clin 2009;59:2741.
  • 16
    Fader AN, Nieves Arriba L, Frasure HE, von Gruenigen VE. Endometrial cancer and obesity: Epidemiology, biomarkers, prevention and survivorship. Gynecol Oncol 2009;114:1217.
  • 17
    Havrilesky LJ, Maxwell GL, Myers ER. Cost-effectiveness of annual screening strategies for endometrial cancer. Am J Obstet Gynecol 2009;200:640. e1-8.
  • 18
    Randall TC, Kurman RJ. Progestin treatment of atypical hyperplasia and well-differentiated carcinoma of the endometrium in women under the age of 40. Obstet Gynecol 1997;90:43440.
  • 19
    Rodriguez GC, Yaqub N, King ME. A comparison of the Pipelle device and the Vabra aspirator as measured by endometrial denudation in hysterectomy specimens: the Pipelle device samples significantly less of the endometrial surface than the Vabra aspirator. Am J Obstet Gynecol 1993;168:559.
  • 20
    Larson DM, Johnson KK, Broste SK, Krawisz BR, Kresl JJ. Comparison of D&C and office endometrial biopsy in predicting final histopathologic grade in endometrial cancer. Obstet Gynecol 1995;86:3842.
  • 21
    Leitao MM Jr, Kehoe S, Barakat RR, Alektiar K, Gattoc LP, Rabbitt C, et al. Comparison of D&C and office endometrial biopsy accuracy in patients with FIGO grade 1 endometrial adenocarcinoma. Gynecol Oncol 2009;113:1058.